Clinical Trial Update: CVN058 Effect on Mismatch Negativity in Schizophrenics [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating CVN058 on mismatch negativity in individuals with schizophrenia; the study has completed and results were posted on 2024-10-04.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• CVN058

Snippet

Sponsor: Cerevance Alpha, Inc. | Conditions: Schizophrenia | Phase 1 | Status: COMPLETED | Results posted: 2024-10-04